Hepatocellular Carcinoma
Conditions
Brief summary
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics).
Detailed description
The aim of this study is to: * Analyze and compare the microbiota and the intestinal, salivary and intratumoral microbiome in patients with HCC, patients diagnosed with oncological pathology and in healthy subjects. The analysis of the mycobiota will be carried out by analyzing bacterial culture media, that of the microbiome by genomic analysis. The evaluation will be made by taking into account multiple taxonomic levels: phylum, class, order, family, genus and species. * Identify tumor antigens (TuAs) with sequence homology with peptides derived from the microbiota/microbiome by bioinformatic analysis. The sequences of tumor antigens known from the literature (https://caped.icp.ucl.ac.be/Peptide/list) will be aligned with sequences derived from bacteria identified in the microbiota/microbiome of patients and healthy subjects.
Interventions
None listed
Sponsors
National Cancer Institute, Naples
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Histological diagnosis of primary HCC and other oncological pathology (Pascale Institute) or diagnosis of oncological pathology (without any exclusions) from an accredited medical-clinical facility (Fortore Mountain Community). * Age ≥18 years * Ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (ICF) and in this protocol. * In the case of paraffin-embedded samples obtained from the UOC of Pathological Anatomy and/or the Institute's Biological Bank, informed consent cannot be acquired, in accordance with the Provision of the Privacy Authority containing the requirements relating to the processing of special categories of data, pursuant to art. 21, paragraph 1 of Legislative Decree 10 August 2018, no. 101, published in the Official Journal - general series - no. 176 of 29/07/2019, point 5 Provisions relating to the processing of personal data carried out for scientific research purposes (gen. aut. n. 9/2016) HEALTHY SUBJECTS * clinical history free from diagnosis of tumor or neoplastic pathology treated during life * Age ≥80 years * Ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (ICF) and in this protocol
Exclusion criteria
* Current pathologies requiring antibiotic therapy * Diagnosis of pre-tumor pathology (in healthy subjects)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification and classification of the numerical variation | approximately 16 months | Identification and classification of the numerical variation (appearance or disappearance) of bacterial species and/or their representativeness (percentage of the total) in the intestinal, salivary and intratumoral microbiota/microbiome of the two groups of enrolled subjects. |
| Identification and classification of the different number and identity of antigens | approximately 16 months | Identification and classification of the different number and identity of antigens predicted by the bacterial species present in the intestinal, salivary and intratumoral microbiota/microbiome of the two groups of enrolled subjects. |
| Identification and classification of the number and identity of TuAs | approximately 16 months | Identification and classification of the number and identity of TuAs that share sequence homology with peptides derived from bacteria that are components of the intestinal, salivary and intratumoral microbiota/microbiome of the two groups of enrolled subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identification of the percentage of memory CD8+ T lymphocytes | approximately 16 months | \- Identification of the percentage of memory CD8+ T lymphocytes in the two groups of enrolled subjects showing cross-reactivity against TuAs and epitopes derived from bacteria that are components of the intestinal, salivary and intratumoral microbiota/microbiome. |
| Identification and classification of numerical variation | approximately 16 months | Identification and classification of the numerical variation (appearance or disappearance) and/or their representativeness (percentage of the total) of the TCR sequences of CD8+ T cells in the two groups of enrolled subjects cross-reactive with TuAs and epitopes derived from bacteria that are components of the intestinal, salivary and intratumoral microbiota/microbiome. |
Countries
Italy
Contacts
Primary ContactLuigi Buonaguro, DR
Outcome results
None listed